Vinpocetine | Vinpocetine-Sar ampoules 0.5%, 2 ml, 10 pcs.

Release form

Solution for injection concentrated

Packing

10 ampoules of 2 ml.

Pharmacological action

Vinpocetine - a drug that improves cerebral circulation. It has a vasodilating, antihypoxic and antiplatelet effect. The mechanism of action is associated with the inhibition of phosphodiesterase, this leads to an increase in the content of cAMP in the cells, which, in turn, it causes a decrease in the calcium content in the cytoplasm of smooth muscle cells and relaxation of myofibrils.

Expands the blood vessels of the brain, enhances blood flow, mainly in ischemic areas, improves the supply of oxygen to the brain. It promotes glucose utilization and increases the level of catecholamines in the central nervous system, stimulates the metabolism of norepinephrine and serotonin in the brain tissue. Reduces platelet aggregation, blood viscosity, increases the deformability of red blood cells and normalizes venous outflow against the background of a decrease in the resistance of cerebral vessels. Systemic blood pressure decreases slightly.

Vinpocetine is effective in the acute period of stroke: it accelerates the regression of cerebral and focal neurological symptoms, improves memory, attention, and intellectual productivity. In the elderly and senile age, the sensitivity of the cerebral vessels to the relaxing effect of vinpocetine increases, which is due to the sensitization of the adenylate cyclase-cAMP system during aging.

Indications

- acute (if parenteral administration is not possible) and chronic forms of cerebrovascular insufficiency (including acute and residual stages of stroke, transient ischemic attack, encephalopathy, dementia after previous cerebrovascular accident)

and vascular diseases or choroid (due to atherosclerosis, angiospasm, thrombosis) degenerative changes in the macula, secondary glaucoma caused by atherosclerosis or angiospasm (due to vascular obstruction)

- age-related vascular or toxic (drug) hearing impairment, Meniere's disease, dizziness of labyrinth origin

- vegetative manifestations of menopausal syndrome.

Contraindications

- severe heart rhythm disturbances

- coronary heart disease (severe course)

- acute stage of hemorrhagic stroke

- pregnancy

- lactation (breastfeeding)

- increased sensitivity to.

Composition

active substance: vinpocetine 5.0 g,

excipients: ascorbic acid, sorbitol, tartaric acid, benzyl alcohol, sodium metabisulfite, water for injection up to 1000 ml.

Dosage and Administration

Intravenous drip. 20 mg is diluted in 250-400 ml of infusion solution. With good tolerance, the dose of the drug is increased 1 mg / kg within 3-4 days, treatment is continued for 10-14 days. After the end of the course of parenteral administration, they switch to the oral administration of the drug. Before discontinuing the drug, the dose should be gradually reduced.

Side effects

Dizziness, feeling of heat, flushing of the face, nausea, thrombophlebitis at the injection site. From the side of the cardiovascular system, a transient decrease in blood pressure, tachycardia, extrasystole, an increase in the time of excitation of the ventricles.

Drug Interactions

Increases the risk of hemorrhagic complications associated with heparin therapy.

Vinpocetine solution is pharmaceutically incompatible with heparin.

Overdose

No cases of overdose of the drug Vinpocetine have been reported.

Treatment: gastric lavage, intake of activated charcoal, if necessary, carry out symptomatic therapy.

Storage conditions

The drug should be stored in a dark place at a temperature of 15 to 35 РC.

Terms and conditions

prescription

dosage form

infusion solution

Biochemist Saransk, Russia